channel blocker

M2 ion channel blocker ,Antiviral agent, is capable of inhibiting and blocking the activity of M2 ion channel.

N-type calcium channel blocker-1 is an orally active analgesic agent with a high affinity for functionally blocking N-type calcium channels.

M2 ion channel blocker-2 (Compound 10) is an inhibitor of the M2 ion channel. It effectively blocks both the wild type and mutant M2 (L27F and V27A) ion channels. This compound exhibits potent antiviral activity against HCoV-229E, with an EC50 of 4.7 μM for cytopathic effect, but shows no efficacy against influenza A virus. Additionally, M2 ion channel blocker-2 does not significantly inhibit hERG or cytochrome P450 enzymes (CYP1A2, CYP2C19, and CYP3A4).

NaV1.2/1.6 channel blocker-1 is a potent inhibitor of NaV1.2 and NaV1.6 channels, exhibiting inhibitory effects on rNaV1.6 and hNaV1.2. This compound can be utilized in the study of generalized epilepsy and movement disorders.

Propafenone (Propafenonum) is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.

Norverapamil is a blocker of L-type calcium channel and an inhibitor of P-glycoprotein (P-gp) function .

Raxatrigine hydrochloride is a state-dependent sodium channel blocker and a Nav1.7 sodium channel inhibitor.

Lanicemine is a low-trapping NMDA channel blocker. It also has a binding (Ki: 0.56-2.1 μM).

Norverapamil hydrochloride (D591 hydrochloride) ((±)-Norverapamil hydrochloride) is an N-demethylated metabolite of Verapamil and it is an L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.

BAI1 hydrochloride is a selective inhibitor of the apoptosis factor BAX, functioning through an allosteric mechanism. By binding to BAX, it allosterically inhibits its activation, showcasing potential applications in the research of diseases mediated by BAX-dependent cell death [1].

Z944 is a T-type calcium channel blocker. Z944 delays the progression of seizures in the amygdala kindling model. Z944 disrupts prepulse inhibition in both epileptic and non-epileptic rats.

A-887826 is a selective, orally bioavailable, and voltage-dependent Na(v1.8) channel blocker (IC50: 11 nM). It attenuates neuropathic tactile allodynia in vivo.

McN5691 (RWJ26240) is a voltage-dependent calcium channel blocker with antihypertensive activity that can be used in the study of diseases caused by vascular smooth muscle abnormalities.

PD0176078 () is a newly blocker of N-type Calcium channel.

PF-06305591 is an effective and selective blocker of voltage-gated sodium channel NaV1.8 (IC50 = 15 nM).

(+)-KCC2 blocker 1 is a selective inhibitor of KCC2 with an IC50 of 0.4 μM.

Tiapamil hydrochloride (Ro 11-1781 hydrochloride) is a calcium channel blocker with antihypertensive activity and may be used in the study of angina and cardiovascular disease.

Naluzotan(PRX 00023) is a novel and potent 5-HT1A agonist with IC50 and Ki values of approximately 20 nM and 5.1 nM, respectively.Naluzotan is a potent hERG K+ channel blocker with an IC50 value of 3800 nM.Naluzotan exhibits anxiolytic activity and can be used to study depression.

PF 04531083 is a selective blocker of the NaV1.8 channel. PF 04531083 can be used for neuropathic and inflammatory pain studies.

Pranidipine (OPC-13340) is a novel, long-acting 1,4-dihydropyridine calcium channel blocker with antihypertensive activity. It enhances acetylcholine-induced relaxation in the presence of endothelium and nitroglycerin-induced relaxation in the absence of endothelium.

Broad spectrum cation channel blocker .This compound is unstable in powder form and other related salt forms are recommended.

Vatanidipine (AE0047) is a novel dihydropyridine (DHP)-type calcium channel blocker with slow-onset pharmacological actions.A slow-onset and long-lasting hypotensive action was observed in various experimental hypertensive models.

AVE-0118 is a potassium channel blocker and suppresses persistent atrial fibrillation.

Lifarizine FA is a sodium channel blocker used in the treatment of neurological disorders and cardiovascular diseases, study of stroke.